UBXN2A and cancer: Furthermore, mortalin inhibitors, including peptides, RNAs, and synthetic and natural small molecules (such as MKT-077, CAPE, embelin, salvianolic acid-B, mortaparib, mortaparibPlus, mortaparibMild, fucoxanthin, UBXN2A, Az-TPP-03, and SHetA2), have shown significant anti-cancer activity mediated by disruption of the mortalin-p53 complex, causing reactivation of p53 function [33,53,54,55,56,57,58,59,60,61,62,63,64,65].